Research

Mixed

Combining anti-obesity pharmacotherapy (phentermine/topiramate) with behavioral and lifestyle interventions yields significant weight loss (-30.5% total body weight) and metabolic improvement in patients with severe obesity (BMI 46 kg/m2) and complex comorbidities, achieving results typically associated with bariatric surgery.

For severe obesity (BMI >40) with comorbidities, combining FDA-approved anti-obesity medications (like phentermine/topiramate or GLP-1 agonists) with intensive lifestyle and behavioral therapy can produce weight loss results comparable to bariatric surgery. This approach is viable even for patients with complex histories (e.g., prior substance use in remission, psychiatric conditions) if carefully monitored by specialists. It serves as a robust alternative or bridge for those who decline or are not candidates for surgery.

LimitedSupportsLOW confidence
Through synergistic and additive treatments (behavioral/nutritional therapy combined with anti-obesity pharmacotherapy and concurrent enrollment in our bariatric surgery program), the patient was able to achieve significant −30.5% total body weight loss with improvement of metabolic parameters.
Gitanjali Srivastava et al. · Frontiers in Endocrinology · 2019

Why this rating

Single case report (n=1), though detailed and long-term (2 years).

Source

Clinical Challenge: Patient With Severe Obesity BMI 46 kg/m2

Gitanjali Srivastava et al. · Frontiers in Endocrinology · 2019

DOI 10.3389/fendo.2019.00635

case_report · n=1Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →